BAYER AG /FI Form SC 13D/A October 14, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Pharmanetics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

71713J107 (CUSIP Number)

Gregory Maloblocki, Esq.
Bayer Corporation
63 North Street
Medfield, MA
02052-1688

with a copy to:
Marilyn Mooney, Esq.
Fulbright & Jaworski L.L.P.
801 Pennsylvania Avenue, NW
Washington, D.C. 20004-2623

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 1, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of this Schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act

but shall be subject to all other provisions of the \mbox{Act} (however, see the \mbox{Notes}).

CUSIP No.	71713J107 Page 2 of 9 Pages			
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bayer Corporation			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) []			
3	SEC USE ONLY			
4	SOURCE OF FUNDS			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)			
6	6 CITIZENSHIP OR PLACE OF ORGANIZATION Indiana			
		7	SOLE VOTING POWER 0	
NUMBER OF SHARES BENEFICIALLY OWNED BY		8	SHARED VOTING POWER 2,050,000	
RE	EACH PORTING PERSON	9	SOLE DISPOSITIVE POWER 0	
	WITH	10	SHARED DISPOSITIVE POW 2,050,000	ER
11	AGGREGATE AMOUNT	BENEFICI.	ALLY OWNED BY EACH REPO	RTING PERSON
	2,050,000			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES SHARES			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.9%			
14 TYPE OF REPORTING PERSON CO				
CUSIP No.	71713J107			Page 3 of 9 Pages
1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bayer Aktiengesellshaft			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			

```
(a) | |
           (b) [ ]
3
           SEC USE ONLY
          SOURCE OF FUNDS
4
5
           CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
           ITEMS 2(d) OR 2(e)
           [ ]
           CITIZENSHIP OR PLACE OF ORGANIZATION
6
           Federal Republic of Germany
                            7
                                     SOLE VOTING POWER
        NUMBER OF
          SHARES
                            8
                                     SHARED VOTING POWER
       BENEFICIALLY
                                     2,050,000
         OWNED BY
                                     SOLE DISPOSITIVE POWER
           EACH
                            9
        REPORTING
          PERSON
           WITH
                            10
                                     SHARED DISPOSITIVE POWER
                                     2,050,000
11
           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
           2,050,000
12
           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES SHARES
           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
           20.9%
          TYPE OF REPORTING PERSON
14
           NAME OF REPORTING PERSON
           S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
           Bayer HealthCare LLC
           CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2
           (a) | |
           (b) [ ]
3
          SEC USE ONLY
4
           SOURCE OF FUNDS
5
           CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
           ITEMS 2(d) OR 2(e)
           [ ]
           CITIZENSHIP OR PLACE OF ORGANIZATION
6
           Delaware
```

		7	SOLE VOTING POWER 0
NUN	MBER OF		
Ç	SHARES	8	SHARED VOTING POWER
BENI	EFICIALLY		2,050,000
OV	WNED BY		
	EACH	9	SOLE DISPOSITIVE POWER
	PORTING		0
Ι	PERSON		
	WITH	10	SHARED DISPOSITIVE POWER 2,050,000
11	AGGREGATE AMOUNT	BENEFICIA	ALLY OWNED BY EACH REPORTING PERSON
	2,050,000		
12	CHECK BOX IF THE	AGGREGATE	E AMOUNT IN ROW (11) EXCLUDES SHARES
13	PERCENT OF CLASS 20.9%	REPRESENT	TED BY AMOUNT IN ROW (11)
14	TYPE OF REPORTING	G PERSON	

CUSIP No. 71713J107

Page 4 of 9 Pages

Item 2. Identity and Background.

This Statement is also being filed by Bayer HealthCare LLC ("BHC"), a Delaware limited liability company with its principal executive offices located at 511 Benedict Avenue, Tarrytown, NY 10591. BHC is a wholly owned subsidiary of the Company. The Company made a capital contribution of its Shares of Common Stock to BHC effective as of January 1, 2003. BHC plans to submit the share certificates to the Issuer for reissuance in its name as record holder.

Information as to the executive officers and directors of the Company, Bayer and BHC is set forth in Exhibits A, B and C hereto.

During the past five years, neither BHC nor, to the Company's knowledge, any of the persons listed in Exhibit A nor, to Bayer's knowledge, any of the persons listed in Exhibit B, nor to BHC's knowledge, any of the persons listed in Exhibit C has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). During the past five years, neither BHC nor, to the Company's knowledge, any of the persons listed in Exhibit A nor, to Bayer's knowledge, any of the persons listed in Exhibit B, nor to BHC's knowledge, any of the persons list in Exhibit C, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 5. Interest in Securities of the Issuer.

(a) As a result of the capital contribution from the Company, BHC beneficially owns the same 2,050,000 shares of Common Stock. To the best knowledge of BHC, no director or executive officer thereof beneficially owns any

shares of Common Stock.

- (b) As the Company and BHC are wholly owned subsidiaries of Bayer, the Company, Bayer and BHC share voting and investment power over the 2,050,000 shares.
- (c) The Company, Bayer and BHC have not and, to the best knowledge of the Company, Bayer and BHC, no director or executive officer of the Company, Bayer or BHC, has effected any transactions in the Common Stock during the past 60 days.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Issuer.

As previously reported in the Schedule 13D dated April 23, 2001, the Company has certain preemptive rights to subscribe to new securities issued by the Issuer on a pro rata basis. The Company waived its preemptive rights with respect to the offering by the Issuer of a \$9,580,000 private placement of preferred stock convertible into common stock at \$6.00 per share and warrants for the purchase of an additional 510,932 common shares at \$7.12 per share. In connection therewith, the Issuer and the Company entered that certain Amendment No. 1 to Common Stock Purchase Agreement dated as of April 30, 2003.

This Amendment modifies and amends the Company's registration rights, preemptive rights and transfer restrictions. With respect to registration rights, the Amendment expands the number of demand registration rights available to the Company as long as the Issuer is Form S-3 eligible, provides certain piggyback registration rights to the Company, and addresses the allocation of registration rights as between the Company and holders of the Series B Preferred Stock.

In addition, the Amendment allows the Company's registration rights and preemptive rights to be transferred along with any transfer of its shares. Finally, the Amendment alleviates and clarifies certain transfer restrictions with respect to shares held by the Company.

The description of the Amendment is qualified in its entirety by reference to such amendment, a copy of which is filed as an exhibit to this statement on Schedule 13D.

and Bayer Corporation

CUSIP No. 71713J107

Page 5 of 9 Pages

Item 7. Material to be Filed as Exhibits.

Exhibit	A	Information	concerning	the	Company's	executive
		officers and	directors.			
Exhibit	В	Information	concerning	Bayer'	's executive	e officers
		and directors	S .			
Exhibit	С	Information	concerning	BHC's	executive	officers
		and directors	3.			
Exhibit	D	Amendment No.	. 1 to Commo	n Stoc	ck Purchase	Agreement
		made as of Ap	oril 30, 200)3 betv	ween Pharman	netics, Inc.

CUSIP No. 71713J107

Page 6 of 9 Pages

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this amendment to this statement is true and correct.

Date: October 14, 2003 BAYER CORPORATION

By: /s/ Joseph A. Akers

Joseph A. Akers

Executive Vice President,

Chief Administrative and Financial Officer

BAYER HEALTHCARE LLC

By: /s/ Frank Wenzel

Frank Wenzel

Vice President, Biltroller and Chief Accounting Officer

BAYER AKTIENGESELLSHAFT

By: /s/ Klaus Kuehn

Klaus Kuehn

Member, Board of Management

Exhibit A

DIRECTORS AND EXECUTIVE OFFICERS OF BAYER CORPORATION

The name, business address, and present principal occupation or employment of each of the directors and executive officers of Bayer Corporation are set forth below. Unless otherwise indicated, the business address of each such director and executive officer is Bayer Corporation, 100 Bayer Road, Pittsburgh, PA 15205-9741. All the directors and executive officers listed below are citizens of the United States, except for Dr. Attila Molnar, Dr. Franz-Josef Berners and Dr. Richard Pott, who are citizens of the Federal Republic of Germany, Ian Paterson, who is a citizen of the United Kingdom, and Emil Lansu, who is a citizen of The Netherlands.

NAME AND BUSINESS ADDRESS PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT

Dr. Attila Molnar..... Director, President and Chief Executive Officer

Dr. Franz-Joseph Berners Bayer AG	Director
Bayer-Werk	
51368 Leverkusen	
Leverkusen, Germany	
Dr. Richard Pott	Director
Bayer AG	
Bayer-Werk	
51368 Leverkusen	
Leverkusen, Germany	
Joseph A. Akers	Executive Vice President, Chief Administrative and Financial Officer
Gary S. Balkema Bayer HealthCare LLC 511 Benedict Avenue Tarrytown, NY 10591	Executive Vice President, Healthcare
Emil Lansu	Executive Vice President, CropScience
Randall S. Dearth	•

A-1

Exhibit B

DIRECTORS AND EXECUTIVE OFFICERS OF BAYER AG

The name, business address, and present principal occupation or employment of each of the directors and executive officers of Bayer AG are set forth below. Unless otherwise indicated, the business address of each such director or executive officer is Bayer Aktiengesellschaft, D-51368 Leverkusen, Federal Republic of Germany. All the directors and executive officers listed below are citizens of the Federal Republic of Germany, except for Mr. Kornblum, who is a U.S. citizen, Mr. Achleitner, who is a citizen of Austria and Mr. Ackermann, who is a citizen of Switzerland.

NAME AND BUSINESS ADDRESS	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
Werner Wenning	Chairman, Board of Management.
Klaus Kuehn	Member, Board of Management.
Dr. Udo Oels	Member, Board of Management.
Richard Pott	Member, Board of Management.
Dr. Manfred Schneider	Chairman, Supervisory Board.
Erhard Gipperich	Vice Chairman, Supervisory Board;
	Chairman, Works Council.
Dr. Paul Achleitner	Member, Supervisory Board;
Allianz AG	Member of Board of Management, Allianz AG.
Koniginstr. 28	
80802 Munchen, Germany	
Dr. Josef Ackermann	Member, Supervisory Board;
Deutsche Bank AG	Spokesman of the Board of Managing Directors
Taunusanlage 12	and Chairman of the Group Executive Committee

60325 Frankfurt, Germany	of Deutsche Bank AG.
Karl-Josef Ellrich	Member, Supervisory Board; Chairman, Works
Bayer AG, Dormagen Plant	Council, Dormagen plant, Bayer AG.
41538 Dormagen, Germany	
Thomas Hellmuth	Member, Supervisory Board;
Bayer CropScience AG	Agricultural Engineer, Langenfeld, Bayer AG.
Elisabeth-Selbert-Str. 4a	
40764 Langenfeld, Germany	
Prof. Dr. Ing. e.h. Hans-Olaf Henkel	Member, Supervisory Board;
Gottfried Wilhelm Leibniz e.V.	President of Leibniz Association;
Friedrichstr. 81	Vice President of the Federation of German Industry.
10117 Berlin, Germany	
Dr. h.c. Martin Kohlhaussen	Member, Supervisory Board; Chairman of
Commerzbank AG	the Supervisory Board, Commerzbank AG.
Kaiserplatz	
60261 Frankfurt am Main, Germany	
John Christian Kornblum	Member, Supervisory Board;
Lazard & Co. GmbH	Chairman of Bankhaus Lazard.
Pariser Platz 4a	
10117 Berlin, Germany	
Petra Kronen	Member, Supervisory Board;
Bayer AG, Uerdingen Plant	Chairman, Works Council, Uerdingen
47812 Krefeld, Germany	plant, Bayer AG.

B-1

NAME AND BUSINESS ADDRESS	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
Dr. Heinrich von Pierer Siemens AG Wittelsbacherplatz 2 80333 Munchen, Germany	Member, Supervisory Board; President and Chief Executive Officer, Siemens AG.
Wolfgang Schenk	Member, Supervisory Board; Graduate Engineer, Bayer AG.
Hubertus Schmoldt	Member, Supervisory Board; Chairman, German Mine, Chemical and Power Workers Union.
Dieter Schulte	Member, Supervisory Board; Former Chairman of the German Unions Federation.
DiplIng. Dr. Ing E.h. Jurgen Weber Deutsche Lufthansa AG von Gablenz - Str. 2 - 6 50679 Koln, Germany	Member, Supervisory Board; Chairman of the Management Board, Deutsche Lufthansa AG.
Sigfried Wendlandt	Member, Supervisory Board; North Rhine District Secretary of the German Mine, Chemical and Power Workers Union.
Reinhard Wendt	Member, Supervisory Board; Printer, Walsrode, Bayer AG.
Thomas de Win	Member, Supervisory Board; Commercial Clerk, Pulheim, Bayer AG.

51519 Odenthal, Germany

Pittsburgh, PA 15205-9741

Prof. Dr. Ernst-Ludwig Winnacker...... Member, Supervisory Board; University Professor.

Deutsche Forschungsgemeinschaft
Kennedyallee 40
53175 Bonn, Germany
Dr. Hermann Wunderlich...... Member, Supervisory Board.

Arndtstrasse 8

Exhibit C

DIRECTORS AND EXECUTIVE OFFICERS OF BAYER HEALTHCARE LLC

The name, business address, and present principal occupation or employment of each of the directors and executive officers of Bayer HealthCare LLC are set forth below. Unless otherwise indicated, the business address of each such director and executive officer is Bayer HealthCare LLC, 511 Benedict Avenue, Tarrytown, NY 10591. All the directors and executive officers listed below are citizens of the United States, except for Dr. Attila Molnar, Markus Arnold, Dr. Gunnar Riemann, Wolfgang Hartwig, and Dr. Frank Wenzel who are citizens of the Federal Republic of Germany, and Rolf Classon, who is a citizen of Sweden.

NAME AND BUSINESS ADDRESS	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
Dr. Attila Molnar	Director and Chairman
Rolf A. Classon	
Markus Arnold	Director Senior Vice President and Senior Administrative Officer
Dr. Gunnar Riemann Bayer HealthCare LLC 79 TW Alexander Drive Research Triangle Park, NC 27709	President, Biological Products Division and Executive Vice President
Gary S. Balkema	President, Consumer Care Division and Executive Vice President
Wolfgang Hartwig	Director Director President, Diagnostics Division and Executive Vice President
John B. Payne Bayer HealthCare LLC 12707 Shawnee Mission Parkway Shawnee, KS 66216-1846	President, Animal Health Division and Senior Vice President
Dr. Frank Wenzel Bayer Corporation 100 Bayer Road	Vice President, Biltroller and Chief Accounting Officer